Product Images Pemetrexed

This is a product label that provides information about a medication or drug that is meant to be used through intravenous injection only. The label includes the warning against the use of the drug for any other purpose. The label also mentions a specific dosage amount for a single-dose vial, including information regarding the fine printing of necessary details like GTIN, Serial Number, EX, LOT, and a barcode encoded with human-readable data. Some obscured text is not available for analysis.*

This is a medication packaging for Pemetrexed injection, USP with a concentration of 500mg per vial. The package contains a barcode for online printing of GTIN, serial number, EXP, LOT, and is encoded with all data presented in human-readable format for easy identification. The medication is for intravenous use only and is a cytotoxic agent. The packaging includes three vials each with an NDC number of 70860-203-50.*

This appears to be a graph or chart showing survival probability over time for patients receiving two different treatments: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). It includes a chart with survival time in months on the horizontal axis and survival probability on the vertical axis. The chart shows survival probability decreasing over time for both treatments, with GC having slightly higher survival probability at each time point. The chart also includes a table showing the number of patients at risk for each treatment at different time points.*

This appears to be a survival analysis chart that shows the probability of survival of patients over a certain time period. The two treatment methods being compared are Pemetrexed for Injection + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The x-axis shows the survival time in months, and the y-axis displays the survival probability. The chart also includes the number of patients at risk for each treatment group at different time points.*

This seems to be a part of a graph that compares the survival time of patients treated with Pemetrexed and Cisplatin (PC) vs. those treated with Gemeitabine and Cisplatin (GC) over a period of 30 months. However, the text is incomplete and without further context, it is difficult to provide more information.*

This appears to be a graph showing survival probability of patients over time during a study of Pemetrexed for Injection, as compared to a placebo. The graph shows the number of patients at risk for the duration of the study (in months) for each treatment group. The number of patients in the Pemetrexed group starts at 441 and decreases to 20 by the end of the study, while the number of patients in the Placebo group starts at 222 and decreases to 0 by the end of the study.*

This is a survival probability table representing the number of patients at risk for both Pemetrexed and Placebo treatments at different time intervals (15, 18, 21 and 24 months) and the corresponding survival time in months.*

This seems to be a table of survival probabilities for patients over a 42 month period, with Pemetrexed for Injection and Placebo being the two treatments compared. The table shows the number of patients at risk at each time point for each treatment.*

This is a survival curve for patients treated with Pemetrexed and Cisplatin. The graph shows the probability of survival over time (in months) for patients. The numbers on the left-hand side represent the patients at risk. The treatment seems to have increased the survival time over no treatment, as the survival probability is higher for the treated group than the untreated group.*

Each vial of this medicine contains 100 mg of Pemetrexed disodium and 106 mg of Mannitol. Hydrochloric Acid and/or Sodium Hydroxide may have been added to adjust the pH. The shelf life of this single-dose vial is until October 25th, 2021. It is important to store the powder at 25°C with excursions between 15° and 30°C. This is a cytotoxic agent for intravenous use only. For the usual dosage, refer to the accompanying literature for instructions on the storage of reconstituted and infusion solutions. The medicine is available from Athenex B and the product is manufactured in the United States.*

NDC 70860-203-50 Beonly is a cytotoxic agent available in the form of a 500mg per vial injection for intravenous use only. Each vial contains pemetrexed disodium equivalent to 10500mg pemetrexed and 500g of mannitol as an additive. Hydrochioric acid and/or sodium hydroride have been added to adjust pH. The powder should be stored at 25°C (77°F). See USP Controlled Room Temperature. Dosage instructions are provided in accompanying literature. The product is manufactured by Athenex in Taiwan, with additional address details in Schaumburg, IL (USA). Lot No. and expiration date are also provided.*